The Bcl-2 inhibitor venetoclax combined with HMAs has achieved ~70% CR or CRi rate in untreated elderly AML patients unfit for conventional intensive chemotherapy (111, 112). This evidence concerns the gene BCL2 and acute myeloid leukemia.